Tango Therapeutics launches $500M common stock offering
Tango Therapeutics, Inc. announced a $500 million underwritten public offering of its common stock, with a 30-day option for underwriters to purchase an additional $75 million. J.P. Morgan, Leerink Partners, Cantor, and Stifel are acting as joint bookrunning managers.
*this image is generated using AI for illustrative purposes only.
Tango Therapeutics, Inc. (NASDAQ: TNGX) launched an underwritten public offering of $500 million of its common stock to raise capital for its clinical-stage biotechnology operations focused on precision cancer medicines. The company intends to grant underwriters a 30-day option to purchase up to an additional $75 million of shares under the same terms. The offering is subject to market conditions, and there is no assurance regarding its completion, size, or terms.
J.P. Morgan, Leerink Partners, Cantor, and Stifel are acting as joint bookrunning managers for the offering. The transaction is being made pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC).
The offering details are summarized below:
| Component | Details |
|---|---|
| Offering Amount | $500 million |
| Additional Option | $75 million |
| Underwriters | J.P. Morgan, Leerink Partners, Cantor, Stifel |
| Regulatory Filing | Effective shelf registration statement |
Tango Therapeutics leverages the genetic principle of synthetic lethality to develop therapies targeting critical cancer mechanisms.
How will the raised capital be allocated across Tango Therapeutics' clinical-stage pipeline?
What impact will this offering have on TNGX's share price and investor sentiment in the short term?
Could this capital raise signal upcoming clinical trial expansions or new drug candidates?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
